Floatz logo

TECHNETATE(3-)-99TC, (N-(4-(((2-AMINO-1,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)-D-.GAMMA.-GLUTAMYL-(2S)-2-(AMINO-.KAPPA.N)-.BETA.-ALANYL-L-.ALPHA.-ASPARTYL-.KAPPA.N-L-CYSTEINATO(6-)-.KAPPA.N,.KAPPA.S)OXO-, HYDROGEN (1:3), (SP-5-24)-

Osteoarthritis

Mayo ClinicSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Osteoarthritis cohort.

Asset / SponsorPhaseRating
Buprenorphine
Mundipharma Pte Ltd.
Phase 4BBB
Naltrexone
Brigham and Women's Hospital
Phase 4BBB
Oxycodone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4BBB
FENTANYL
Janssen Pharmaceutica
Phase 4BBB
Duloxetine
The Catholic University of Korea
Phase 4BBB

View all 48 →

Same molecule, other indications

TECHNETATE(3-)-99TC, (N-(4-(((2-AMINO-1,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)-D-.GAMMA.-GLUTAMYL-(2S)-2-(AMINO-.KAPPA.N)-.BETA.-ALANYL-L-.ALPHA.-ASPARTYL-.KAPPA.N-L-CYSTEINATO(6-)-.KAPPA.N,.KAPPA.S)OXO-, HYDROGEN (1:3), (SP-5-24)- is also rated in:

rheumatoid arthritisDormant
B
Indicative ·
57 / 100
View asset →
Crohn diseaseDormant
B
Indicative ·
57 / 100
View asset →
systemic lupus erythematosusDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →